The stock price of Cassava Sciences (NASDAQ: SAVA) plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental ...

Shares of Cassava Sciences (NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, ...

After rising over $100 briefly this year, Cassava Sciences (NASDAQ:SAVA) stock is struggling to rebound. A long document written by the lawyer of a short-seller sent SAVA stock lower. The document ...

Cassava Sciences , a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative diseases, such as Alzheimer’s disease (AD), is expected to report fourth-quarter ...

Casava Sciences (NASDAQ:SAVA) stock jumped 9% Wednesday after the pharmaceutical company released promising data related to its clinical study of Simfilam, its proposed treatment for ...

On Tuesday, Cassava announced that investors in its common stock would be paid a rather offbeat dividend: For every 10 shares they own, they are to receive four common stock warrants. Each of these ...

Shares of Cassava Sciences (NASDAQ: SAVA) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on ...